HIF1A and primary cutaneous T-cell non-Hodgkin lymphoma: Suberoylanilide Hydroxamic Acid (SAHA), an HDACi that has been approved for the treatment of cutaneous T cell lymphoma (CTCL), has been found to down-regulate HIF-1α protein levels.